Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation
August 26, 2020
In another victory on behalf of Axinn’s client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy’s Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior’s opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
Hartford HealthCare Black and Red Gala 2025
Sponsorship
Antitrust
Informa CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
IAM Live: Auto IP USA 2025
Speaking Engagement
Intellectual Property
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Biosimilars Litigation and Client Counseling
Byline Articles
A Labor of Love: Trump DOJ Obtains First Guilty Verdict in a Criminal Labor Case
Axinn Viewpoints
Antitrust